AURA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
35.1M
-27.1%
48.1M
+37.9%
34.9M
+28.0%
27.2M
-2.4%
27.9M
R&D
24.7M
-19.5%
30.7M
+10.0%
28.0M
+27.7%
21.9M
-1.3%
22.2M
SG&A
10.3M
-40.4%
17.3M
+150.8%
6.9M
+29.3%
5.3M
-6.8%
5.7M
Operating Income
-35062000
+27.1%
-48069000
-37.9%
-34866000
-28.0%
-27237000
+2.4%
-27906000
EBITDA
-34811000
+27.2%
-47809000
-38.2%
-34592000
-28.3%
-26965000
+2.4%
-27626000
Net Income
-32066000
+29.7%
-45637000
-35.5%
-33685000
-31.8%
-25559000
+2.2%
-26130000
EPS (Basic)
$-0.29
+39.6%
$-0.48
+4.0%
$-0.50
-31.6%
$-0.38
+5.0%
$-0.40
EPS (Diluted)
$-0.29
+39.6%
$-0.48
+4.0%
$-0.50
-31.6%
$-0.38
+5.0%
$-0.40
Shares (Diluted)
111.1M
+17.1%
94.9M
+40.6%
67.4M
+0.3%
67.3M
+2.0%
65.9M
Aura Biosciences (AURA) — Financials